ActivePhase 4ACTRN12610000697088

Ciclosporine Azathioprine versus Tacrolimus mycophenolate mofetil in renal transplantation

A randomized prospective open trial comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil , associated to rabbit anti-thymocyte globulines (rATG) induction and prednisone in kidney transplantation

Sponsor

Assistance publique des Hopitaux de Marseille

Enrollment

300 participants

Start Date

Feb 1, 2000

Study Type

Interventional

Conditions

Immunosuppressive treatment in renal transplantation Acute rejection and transplant survival in renal transplantation

Summary

Randomized and open monocentral trial evaluating 2 immunosupressive regiments in prevention of acute rejection in renal transplantation.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares two different combinations of anti-rejection drugs for people receiving a kidney transplant. You must be aged 18 to 65, have chronic kidney failure requiring a transplant, and test negative for hepatitis B. The study aims to determine which drug combination works better for preventing organ rejection.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Tacrolimus 0.075 mg/Kg/twice daily oral tablet & mycophenolate mofetil 1000 mg/twice daily oral tablet. The duration of the two treatments is prolonged during all the graft survival duration.

Locations(1)

bouches du rhone, France

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000697088